ENvue Medical develops robotic feeding tube placement system

therobotreport.com Jul 29, 2026

ENvue Medical develops robotic feeding tube placement system

Curated by Shubham · TechCapsules · Jul 29, 2026

AI-summarised brief · reviewed before publication

ENvue Medical Inc. has unveiled ENvue Drive, a robotic-assisted system designed to automate feeding tube placement. Built upon the company’s existing FDA-cleared electromagnetic navigation platform, the device integrates artificial intelligence and real-time tracking to guide tubes safely into the small intestine. Currently, over one million feeding tubes are inserted annually in the U.S., often blindly by nurses or dietitians. Approximately three to five percent of these procedures result in misplaced tubes entering the lungs, causing severe complications like lung collapse. ENvue Drive utilizes an in-house sensor with a high refresh rate to provide immediate, GPS-like visual feedback to clinicians. The system accounts for patient movement using additional ECG sensors, ensuring accuracy even if the patient shifts. By automating the insertion process while keeping clinicians in supervisory control, ENvue aims to reduce errors, enhance patient safety, and alleviate pressure on understaffed medical teams.

💡 Why It Matters

· By replacing blind insertion with precise robotic guidance, the technology directly addresses a critical safety gap where misplaced tubes cause life-threatening lung injuries.
· This innovation transforms a high-stress, error-prone manual task into a standardized, supervised procedure, potentially saving lives and reducing hospital costs associated with corrective interventions.

Read full article on therobotreport.com

Smith+Nephew’s TESSA Spatial Surgery System granted De Novo classification by the FDA…

Smith+Nephew announced that the U.S. Food and Drug Administration granted De Novo classification for its TESSA Spatial Surgery System. This regulatory approval marks the first device in a new FDA category for intra-articular orthopedic stereotaxic navigation instruments. The system utilizes AI, augmented reality, and real-time tracking to enhance arthroscopic procedures. It generates patient-specific 3D anatomical models from preoperative scans, overlaying them onto live 4K video to assist surgeons. The initial indication is for femoral tunnel placement during anterior cruciate ligament reconstruction, addressing common causes of surgical failure like malposition. Developed using technology from acquired Perceive3D S.A., the platform runs on AWS and NVIDIA infrastructure. Experts note this innovation supports clinical decision-making rather than replacing it. The classification establishes a regulatory reference point for future digital sports medicine tools, reinforcing Smith+Nephew’s position in personalized, data-enabled surgical solutions. This milestone signifies a generational leap in procedural precision and personalized planning for orthopedic surgeons treating knee injuries.

💡 By establishing a new regulatory category, this approval creates a precedent for AI-driven surgical navigation tools, potentially accelerating the adoption of augmented reality in orthopedics. It shifts the industry focus from implant-centric solutions to data-enabled procedural precision, setting a new standard for reducing surgical errors in complex reconstructions.

thequantuminsider.com · Jul 28

Guest Post — Beyond Silicon: How AI Is Accelerating the Next Era…

Ian Foley argues that the current AI boom is straining silicon-based infrastructure, necessitating a shift toward a post-silicon computing stack. While immediate capital flows into data centers to meet urgent capacity demands, classical architectures are ill-suited for long-term scalability. The emerging solution integrates AI, quantum computing, and biocomputing. Quantum firms like IBM and IonQ are advancing hardware paths such as superconducting qubits and photonics to solve complex problems in molecular simulation and cryptography. Simultaneously, biocomputing pioneers like Cortical Labs and Biomemory are developing neuron-based systems and DNA storage for ultra-dense archiving. This triad positions AI as the intelligence layer, quantum as the simulation engine, and biology as the efficient storage medium. The transition moves beyond expanding server farms toward a smarter, hybrid ecosystem. This evolution addresses the physical limits of electricity grids and traditional logic, offering a sustainable path for future computational growth without relying solely on brute-force silicon expansion.

💡 The convergence of quantum and biological computing offers a tangible escape from the physical limits of silicon, redefining how we solve complex problems. This shift moves the industry beyond brute-force scaling toward a more efficient, multi-layered computational architecture.

artificialintelligence-news.com · Jul 28

Guardoc Health processes clinical documentation using Amazon Nova models

Guardoc Health processes over one million clinical documents daily using Amazon Nova models via Bedrock, aiming to reduce errors in long-term care documentation. The system addresses complex inputs like handwritten annotations and mixed-format forms, which often lead to denied Medicare claims and audit fines. Guardoc reports a 46 percent reduction in documentation errors and a 70 percent drop in audit fines. In a quarterly deployment across two facilities, the system drove 847 corrections and flagged 86 reimbursement issues, correlating with a 74 percent reduction in hospital transfers. A separate study of seven facilities identified 10,612 issues. The architecture uses retrieval augmented generation, employing Amazon Textract for initial extraction and Amazon Titan embeddings for storage. Cost-tiering logic reserves computationally intensive Amazon Nova Pro reasoning for final classification stages, while cheaper components handle high-volume filtering. This approach targets specific pain points like physician attestation fields and medication extraction, where handwriting often overrides printed data. Guardoc claims over $400,000 in annual ROI per facility, though baseline methodologies remain unpublished. The technology seeks to mitigate diagnostic errors affecting millions of US outpatients annually by improving information handling accuracy in clinical records.

💡 By isolating expensive multimodal reasoning for only the most complex handwritten elements, Guardoc demonstrates a viable path to scaling AI in healthcare without prohibitive costs. This efficiency directly tackles the financial and safety risks inherent in the Patient-Driven Payment Model, where documentation accuracy dictates reimbursement and patient outcomes.

artificialintelligence-news.com · Jul 27

How AI is shortening drug discovery timelines in China

Insilico Medicine CEO Alex Zhavoronkov stated that the company has reduced drug candidate development timelines to approximately one year by integrating artificial intelligence with laboratory research in China. This approach contrasts with conventional methods, which typically require four-and-a-half years to reach the same stage. The Hong Kong-listed firm uses generative AI to identify biological targets and design molecules, while its Shanghai facility handles experimental validation and scale-up. Insilico reported generating 31 preclinical candidates since 2021, with 13 receiving investigational new drug clearances. Zhavoronkov attributed the accelerated cycle to China’s research infrastructure, lower operating costs, and favorable regulatory environment, noting that pharmaceutical companies can remove about two years from traditional timelines. The company competes on speed against Chinese firms and on novelty against Western biotechs. Insilico has secured agreements with Eli Lilly and Takeda, and announced a potential $2.5 billion alliance with Bora Pharmaceuticals. Despite its Chinese operations, over 90% of Insilico’s revenue originates from Western pharmaceutical companies due to higher reimbursement rates. The company plans to expand its Shanghai research facilities while limiting software sales in China due to geopolitical concerns.

💡 China’s shift from generic manufacturing to rapid, AI-driven innovation forces Western biotechs to compete on speed rather than just novelty. This structural advantage, combined with lower costs, redefines global R&D efficiency benchmarks.

newsfirstprime.com · Jul 25

Bengaluru Tech Summit 2026 from Nov 17; Set to host 60,000+ visitors,…

The Karnataka government announced the 29th Bengaluru Tech Summit, scheduled for November 17‑19, 2026, under the theme “AI & Beyond.” Organisers project more than 60,000 business visitors, 25,000 delegates, 1,800 exhibitors and 1,000 startups from over 75 nations and 30 Indian states and union territories. The three‑day event will showcase conferences, exhibitions and investor‑connect sessions across AI, DeepTech, semiconductors, biotechnology, fintech, spacetech, AVGC, digital infrastructure and electric mobility. Chief Minister D.K. Shivakumar unveiled a new DeepTech roadmap, startup funding schemes and semiconductor initiatives alongside the summit. The gathering aims to cement Bengaluru’s status as India’s premier technology and innovation hub by fostering global partnerships and showcasing emerging technologies.

💡 The summit positions Bengaluru as the focal point for next‑generation tech collaboration, drawing unprecedented international participation to accelerate India’s DeepTech ecosystem.

timeskuwait.com · Jul 25

Europe approves PRIMA eye implant to help restore sight in blind patients

Science Corporation, a developer of brain‑computer interfaces, has secured European regulatory clearance for its PRIMA vision‑restoration system, a retinal implant paired with camera‑equipped smart glasses designed for patients with advanced age‑related macular degeneration. The device, which received FDA Breakthrough Device designation, is implanted beneath the retina in an hour and receives wireless image data from the glasses to stimulate remaining retinal cells, restoring sight. Clinical data show a French patient reading a 300‑page novel and others completing puzzles or drawing recognizable images. Founder Max Hodak, a former Neuralink executive, launched the company in 2021 and entered retinal market after acquiring Pixium Vision in 2024. Commercial rollout begins in Germany, with implants expected by September, and pricing discussions underway with insurers.

💡 Restoring functional vision for macular degeneration patients could transform daily independence for millions previously considered untreatable.